Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HM30181A + Topotecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HM30181A | HM30181AK|Encequidar|HM-30181A | HM30181A (Encequidar) inhibits the ABC transporter protein P-glycoprotein, which may reduce cellular efflux of chemotherapeutic agents (PMID: 25038758). | ||
| Topotecan | Hycamtin | Topotecan Hcl | Topotecan binds to topoisomerase I and stablizes complexes with DNA, resulting in decreased repair of DNA single-strand breaks, and potentially leading to cell death (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03987685 | Phase I | HM30181A + Topotecan | Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies | Completed | USA | GBR | 0 |